World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
120
Citations
72285
World Ranking
3678
National Ranking
366

Overview

Howard A. Burris is affiliated with the Sarah Cannon Research Institute in the United Kingdom. Their research portfolio spans several key areas within medicine and biochemistry, genetics, and molecular biology, with a significant focus on oncology and related subfields.

Their work is heavily concentrated in oncology, pulmonary and respiratory medicine, molecular biology, cancer research, and surgery. These areas reflect a multidisciplinary approach to cancer treatment and underlying biological mechanisms.

Main research topics studied by Howard A. Burris include:

  • Cancer Genomics and Diagnostics
  • Advanced Breast Cancer Therapies
  • Cancer Immunotherapy and Biomarkers
  • Cholangiocarcinoma and Gallbladder Cancer Studies
  • Lung Cancer Treatments and Mutations
  • Colorectal Cancer Treatments and Studies
  • HER2/EGFR in Cancer Research

Burris has published extensively in multiple notable scientific venues. Frequent publication venues include:

  • Journal of Clinical Oncology
  • Cancer Research
  • Annals of Oncology
  • Clinical Cancer Research
  • British Journal of Cancer

Key recent papers authored or co-authored by Burris encompass a range of clinical and therapeutic studies, including:

  • Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer, 2022, NEJM Evidence
  • Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study, 2021, The Lancet Oncology
  • Ivosidenib in Isocitrate Dehydrogenase 1-Mutated Advanced Glioma, 2020, Journal of Clinical Oncology
  • First-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced tumors, 2021, EClinicalMedicine
  • A phase 3 randomized, double-blind, placebo-controlled study of durvalumab in combination with gemcitabine plus cisplatin (GemCis) in patients (pts) with advanced biliary tract cancer (BTC): TOPAZ-1, 2022, Journal of Clinical Oncology

Throughout their career, Burris has frequently collaborated with a number of other researchers. Frequent co-authors include:

  • David R. Spigel
  • Suzanne F. Jones
  • Do-Youn Oh
  • Manish R. Patel
  • Mohamed Bouattour

Best Publications

  • Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: A single-arm, multicentre, phase 2 trial

    Jonathan E Rosenberg;Jean Hoffman-Censits;Tom Powles;Michiel S van der Heijden

  • Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer

    José Baselga;Mario Campone;Martine Piccart;Howard A. Burris

  • Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations

    Keith T. Flaherty;Jeffery R. Infante;Adil Daud;Rene Gonzalez

  • MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

    Thomas Powles;Joseph Paul Eder;Gregg D. Fine;Fadi S. Braiteh

  • Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer

    Gabriel N. Hortobagyi;Salomon M. Stemmer;Howard A. Burris;Yoon-Sim Yap

  • Capecitabine as Adjuvant Treatment for Stage III Colon Cancer

    Chris Twelves;Alfred Wong;Marek P. Nowacki;Markus Abt

  • Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial

    Paul M Ridker;Jean G MacFadyen;Tom Thuren;Brendan M Everett

  • Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab.

    Shirin Khambata-Ford;Christopher R. Garrett;Neal J. Meropol;Mark Basik

  • EPIC: Phase III Trial of Cetuximab Plus Irinotecan After Fluoropyrimidine and Oxaliplatin Failure in Patients With Metastatic Colorectal Cancer

    Alberto F. Sobrero;Joan Maurel;Louis Fehrenbacher;Werner Scheithauer

  • Phase II Study of the Antibody Drug Conjugate Trastuzumab-DM1 for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2) –Positive Breast Cancer After Prior HER2-Directed Therapy

    Howard A. Burris;Hope S. Rugo;Svetislava J. Vukelja;Charles L. Vogel

  • Phase I, dose-escalation study of BKM120, an oral pan-class I PI3K inhibitor, in patients with advanced solid tumors

    Johanna C. Bendell;Jordi Rodon;Howard A. Burris;Maja de Jonge

  • Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer.

    Gabriel N. Hortobagyi;Salomon M. Stemmer;Howard A. Burris;Yoon-Sim Yap

  • First-in-Humans Trial of an RNA Interference Therapeutic Targeting VEGF and KSP in Cancer Patients with Liver Involvement

    Josep Tabernero;Geoffrey I. Shapiro;Patricia M. LoRusso;Andres Cervantes

  • Phase I Study of Trastuzumab-DM1, an HER2 Antibody-Drug Conjugate, Given Every 3 Weeks to Patients With HER2-Positive Metastatic Breast Cancer

    Ian E. Krop;Muralidhar Beeram;Shanu Modi;Suzanne F. Jones

  • Dose- and Schedule-Dependent Inhibition of the Mammalian Target of Rapamycin Pathway With Everolimus: A Phase I Tumor Pharmacodynamic Study in Patients With Advanced Solid Tumors

    Josep Tabernero;Federico Rojo;Emiliano Calvo;Howard Burris

  • Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2

    M. Piccart;G. N. Hortobagyi;M. Campone;K. I. Pritchard

  • Rituximab as First-Line and Maintenance Therapy for Patients With Indolent Non-Hodgkin’s Lymphoma

    John D. Hainsworth;Sharlene Litchy;Howard A. Burris;Daniel C. Scullin

  • Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial.

    Gerald S Falchook;Karl D Lewis;Jeffrey R Infante;Michael S Gordon

  • Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis

    Denise A. Yardley;Shinzaburo Noguchi;Kathleen I. Pritchard;Howard A. Burris

  • Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial

    Jeffrey R. Infante;Leslie A. Fecher;Gerald S. Falchook;Sujatha Nallapareddy

Frequent Co-Authors

Jeffrey R. Infante
Jeffrey R. Infante Janssen (Belgium)
John D. Hainsworth
John D. Hainsworth Sarah Cannon Research Institute
David R. Spigel
David R. Spigel Sarah Cannon Research Institute
F. Anthony Greco
F. Anthony Greco Sarah Cannon Research Institute
Johanna C. Bendell
Johanna C. Bendell Sarah Cannon Research Institute
Patricia LoRusso
Patricia LoRusso Yale University
José Baselga
José Baselga Memorial Sloan Kettering Cancer Center
Hope S. Rugo
Hope S. Rugo University of California, San Francisco
Kathleen N. Moore
Kathleen N. Moore University of Oklahoma Health Sciences Center
Mario Campone
Mario Campone Grenoble Alpes University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you’re planning to study Medicine in the USA, you may also want to explore alternative health-related career paths, many of which can be started online. For those still in high school or looking to prepare early, the best online schools for high school students offer affordable introductory programs in health information management. These courses can provide a solid foundation before committing to a longer degree.

Careers in healthcare administration and support are also in high demand. If you’re interested in working with medical records without attending a traditional campus, you can find the cheapest medical billing and coding online courses that offer flexible, accredited training.

For aspiring nurses, there are now many options for cheapest np school online as well as affordable online nursing courses to help you start or advance your nursing career. These programs are designed for those seeking flexible pathways into the healthcare field and can often be completed while working or managing other commitments.

Best Scientists Citing Howard A. Burris

Trending Scientists